Successful treatment of chronic hepatitis C in a kidney transplant patient with only 2 weeks of direct-acting antiviral therapy

De Sá Guimarães Cerqueira, Sofia; Dinis Mesquita, Mónica; Arlindo Castro, Rui; Carrola, Paulo; Morgado, Teresa Margarida Pinto Ribeiro; Marques, Paula.
Nefrología (Madrid) ; 38(6): 671-672, nov.-dic. 2018.
Artículo en Inglés | IBECS (España) | ID: ibc-178403

Documentos relacionados

  1. Sustained virologic response with 6 weeks or less of direct-acting antiviral therapy for chronic hepatitis C: Experience at a veterans affairs healthcare system.
  2. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.
  3. Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response.
  4. Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project.
  5. A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C.
  6. Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations.
  7. Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients.
  8. Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients.
  9. Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection.
  10. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.